Table 1. Patient-reported reasons for discontinuation of SQ anti-TNF in past 12 months
| Reasons | Primary | Other* | Primary and Other* |
|---|---|---|---|
| Lack of Effectiveness | 40.8% | 27.6% | 60.8% |
| Injection Experience | 18.4% | 34.0% | 40.8% |
| Cost or Reimbursement Issues | 12.0% | 21.2% | 27.6% |
| Safety | 11.6% | 17.6% | 26.0% |
| Remission (Partial or Complete) | 7.2% | 3.2% | 10.4% |
| Other | 10.0% | 9.2% | 19.2% |
*Sums to greater than 100% due to multiple response.